Kyverna Therapeutics announces updated data from Phase 1 IITs of KYV-101

Kyverna Therapeutics (KYTX) announced updated data from Phase 1 investigator-initiated trials, IITs, of KYV-101 in the treatment of progressive multiple sclerosis, MS, to be presented at the 2025 European Committee for Treatment and Research in Multiple Sclerosis, ECTRIMS, Congress, taking place in Barcelona, Spain from September 24-26, 2025. Data presented will include an oral presentation from Stanford Medicine, Department of Neurology & Neurological Sciences and a poster presentation from the University of California, San Francisco, Weill Institute for Neurosciences. “Encouraging KYV-101 IIT data in multiple sclerosis underscores the therapy’s broad potential within neuroimmunology autoimmune diseases, including stiff person syndrome and myasthenia gravis,” said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics. “We are grateful to our partners at Stanford and UCSF for leading these important studies exploring the potential of CAR T-cell therapy in treating a disease that affects millions of people and carries significant unmet need. As data continue to mature, we look forward to using these insights to inform our path forward.”